Spago Nanomedical
LUND, SWEDEN / ACCESSWIRE / December 6, 2021 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)
Spago Nanomedical AB (publ) today announced it has completed the studies in the regulatory preclinical program with its leading candidate drug Tumorad (SN201). It displays a good safety margin to clinically relevant doses.
"The completion of the regulatory preclinical studies is an important step towards the clinical development phase. The preparations for the first study with SN201 in humans are proceeding according to plan and we expect to be ready to start phase I/II in next year ", said CEO Mats Hansen.
The preclinical package included toxicology- and dosimetry-studies in rat. The results showed that the nanomaterial is safe to give in doses that widely exceed planned clinical doses, and that radiation is distributed in the body in a manner that allow dosing according to plan.
"The results confirm the data we previously have seen in pilot studies and mean that we with confidence can proceed with SN201 to the clinic. This is a major risk reduction in the project ", said Oskar Axelsson, CSO at Spago Nanomedical.
Data from the preclinical studies, together with other documentation, will form the basis for the first clinical trial application with Tumorad. The plan is to submit the application and start the studies in humans in 2022. The aim for the clinical study is to document safety at different doses of Tumorad in cancer patients as well as to evaluate signs of early proof-of-concept.
The preclinical regulatory program, conducted in collaboration with Charles River Laboratories and Minerva Imaging, included both toxicity and dosimetry studies.
For further information, please contact Mats Hansen, CEO Spago Nanomedical AB, +46 46 811 88, mats.hansen@spagonanomedical.se
Spago Nanomedical AB is a Swedish nanomedicines company in clinical development phase. The company´s development projects are based on a platform of polymeric materials with unique properties for more precise diagnosis and treatment of solid tumors. Spago Nanomedical´s share is listed on Nasdaq First North Growth Market (ticker: SPAGO). For further information, see www.spagonanomedical.se.
FNCA Sweden AB is the Certified Adviser of the company, +46 8 528 00 399, info@fnca.se .
This information is information that Spago Nanomedical is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2021-12-06 08:00 CET.
Attachments
Tumorad® shows good safety in preclinical studies
SOURCE: Spago Nanomedical
View source version on accesswire.com:
https://www.accesswire.com/676127/TumoradR-Shows-Good-Safety-in-Preclinical-Studies
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Cyara Appoints Sushil Kumar as CEO to Extend Enterprise AI Customer Experience (CX) Leadership8.12.2025 22:30:00 CET | Press release
Visionary AI and cloud executive with proven record of building and scaling enterprise platforms to lead the next phase of innovation and global expansion for the CX assurance market leader. AUSTIN, TX / ACCESS Newswire / December 8, 2025 / Cyara, the global leader in AI-powered customer experience (CX) assurance, today announced the appointment of Sushil Kumar as its new Chief Executive Officer. His appointment underscores Cyara's commitment to accelerating enterprise AI CX innovation and elevating customer experience by enabling more reliable, responsive, and trustworthy interactions across every channel. Sushil will build on the strong foundation laid by outgoing CEO Rishi Rana. Sushil brings entrepreneurial vision and enterprise-scale leadership to Cyara. He has focused his career on building category-defining AI, DevOps, and cloud platforms, both as a founder and as a leader of large global organizations. Most recently, he was Co-Founder and CEO of RelicX.ai, a generative AI test
AI21 Labs and Fnac Darty, Partner to Drive Retail AI Transformation8.12.2025 09:00:00 CET | Press release
Fnac Darty selects AI21 as a strategic AI partner to tackle retail's most complex challenges, starting with After-Sales service, with Maestro, the leading AI orchestration platform. PARIS, FR AND TEL AVIV, IL / ACCESS Newswire / December 8, 2025 / AI21 labs, a frontier AI developer and a global leader in enterprise AI, announced a strategic partnership with Fnac Darty, one of Europe's leading retailers with a network of both online and physical stores. The collaboration marks a flagship initiative in Fnac Darty's long-term growth strategy and positions AI21 as a strategic partner for the rollout of AI across the company's operations. The partnership supports Fnac Darty's recently announced "Beyond Everyday" strategic plan, which focuses on accelerating the company's transition from a product-based model to services and subscriptions, with After-Sales at the heart of this evolution. The first use case will focus on after-sales service, a mission-critical area for Fnac Darty and a corner
The 13th GLA Global Logistics Conference Successfully Concludes in Bangkok, Thailand5.12.2025 16:00:00 CET | Press release
More than 2,000 logistics leaders from 130+ countries convene in Thailand to advance peace, digital innovation and trustworthy cooperation in global supply chains. SHENZHEN, CN / ACCESS Newswire / December 5, 2025 / The 13th GLA Global Logistics Conference was successfully held in Bangkok, Thailand from November 7-10, 2025, providing a prestigious international platform for business cooperation in the global logistics sector. Co-organized by the Global Logistics Enterprises Federation (GLEF) and the GLA Global Logistics Alliance, the event centered around the theme "Peaceful Prosperity, Digital Innovation, Trustworthy Cooperation." The conference brought together over 2,000 logistics professionals and industry leaders from more than 130 countries, fostering a unique environment for collaboration and knowledge exchange. With its exceptional industry influence and capacity for cross-border resource integration, GLA continues to emerge as a pivotal force in driving global supply chain inn
OMP's AI-driven Unison Planning(TM) Platform Enhances Supply Chain Agility for McCormick & Co.3.12.2025 15:00:00 CET | Press release
ATLANTA, GEORGIA / ACCESS Newswire / December 3, 2025 / OMP is helping McCormick & Co., the global leader in flavor, with an AI-driven and autonomous operational planning initiative. This partnership enables McCormick to manage both assembly-to-order (ATO) and make-to-stock (MTS) production within the Unison PlanningTM platform. The initiative tackles key challenges, including balancing ATO and MTS production on shared lines, improving inventory projections through quality-based stock releases, and managing capacity amid fluctuating demand. Addressing these challenges requires close collaboration across regions with North American and EMEA teams working in parallel, and seamless integration of SAP with the operational planning functionality within Unison Planning™. The first implementations will roll out in Canada and the United States before expanding to the EMEA and APAC regions. Through its partnership with OMP, McCormick is implementing autonomous, decision-centric planning powered
Oman's 10-Year Golden Residency Program Attracts Global Investors Seeking Stability and Long-Term Access3.12.2025 14:00:00 CET | Press release
Built for investors who value certainty, global access, and long-term confidence. MUSCAT, OM / ACCESS Newswire / December 3, 2025 / Three months after its introduction, Oman's 10-Year Golden Residency is emerging as one of the region's most compelling long-term residency pathways, attracting rising interest from investors, entrepreneurs, and internationally mobile families seeking stability, transparent regulation, and strategic access to high-growth markets. The programme-launched under Oman Vision 2040-offers a structured framework for investors wishing to establish deeper roots in a country positioning itself as a secure and globally connected economic hub.Prosperity and Liveability in Oman.jpg A contemporary Omani setting featuring growth, safety, and quality-of-life elements that define the country's reputation for prosperity and liveability. The Golden Residency grants eligible applicants long-term residency in return for a minimum investment of USD 520,000 across seven clearly d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom